Emergency management of community-acquired bacterial pneumonia: What is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines

American Journal of Emergency Medicine

Volumn 31, Issue 3, 2013, Pages 602-612

  Moran, Gregory J ^a   Rothman, Richard E ^b   Volturo, Gregory A ^c  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL; CLINDAMYCIN; ERYTHROMYCIN; LINEZOLID; PENICILLIN G; PROCALCITONIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; EMERGENCY WARD; EMPIRICAL RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; KLEBSIELLA PNEUMONIAE; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR DIAGNOSIS; MORBIDITY; MORTALITY; NONHUMAN; PHYSICIAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DECISION SUPPORT TECHNIQUES; EMERGENCY TREATMENT; HOSPITALIZATION; HUMANS; INTENSIVE CARE; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, STAPHYLOCOCCAL; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 84875422967     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2012.12.002     Document Type: Review

References (117)

1. S.M. Schappert, and E.A. Rechtsteiner Ambulatory medical care utilzation estimates for 2007 Vital Health Stat 13 169 2011 1 38
2. M.J. Hall, C.J. DeFrances, and S.N. Williams National Hospital Discharge Survey: 2007 Summary National Health Statistics Reports; no 29 2010 National Center for Health Statistics Hyattsville, MD
3. T.J. Marrie, and M.R. Shariatzadeh Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study Medicine (Baltimore) 86 2007 103 111
4. M.I. Restrepo, E.M. Mortensen, and J.A. Velez A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU Chest 133 2008 610 617
5. S.F. Jencks, M.V. Williams, and E.A. Coleman Rehospitalizations among patients in the Medicare fee-for-service program N Engl J Med 360 2009 1418 1428
6. M.L. Jackson, K.M. Neuzil, and W.W. Thompson The burden of community-acquired pneumonia in seniors: results of a population-based study Clin Infect Dis 39 2004 1642 1650
7. Miniño AM, Murphy SL, Xu J, et al. Deaths: final data for 2008. National vital statistics reports; vol 59 no 10. Hyattsville, MD: National Center for Health Statistics. 2011. http://www.cdc.gov/nchs/data/nvsr/nvsr59/ nvsr59-10.pdf.
8. S. Ewig, N. Birkner, and R. Strauss New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality Thorax 64 2009 1062 1069
9. T.M. File Jr., and T.J. Marrie Burden of community-acquired pneumonia in North American adults Postgrad Med 122 2010 130 141
10. Joint Commission. Pneumonia Measures. http://www.jointcommission.org/ pneumonia/ Accessed September 7, 2012.
11. Gesensway D. New thinking on antibiotic timing in CAP patients. Today's Hospitalist. March 2008. www.todayshospitalist.com/index.php?b=articles- read&cnt=526. Accessed August 30, 2012.
12. C. Fee, E.J. Weber, and P. Bacchetti Effect of emergency department crowding on pneumonia admission care components Am J Manag Care 17 2011 269 278
13. G.J. Moran, D.A. Talan, and F.M. Abrahamian Diagnosis and management of pneumonia in the emergency department Infect Dis Clin North Am 22 2008 53 72
14. D.J. Nazarian, O.L. Eddy, and T.W. Lukens Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia Ann Emerg Med 54 2009 704 731
15. L.A. Mandell, R.G. Wunderink, and A. Anzueto Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 Suppl 2 2007 S27 S72
16. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for industry, community-acquired bacterial pneumonia: developing drugs for treatment (draft guidance). Rockville, MD: US Dept of Health and Human Services; March 2009.
17. H. Goto, K. Shimada, and H. Ikemoto Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study J Infect Chemother 15 2009 347 360
18. H. Wang, M. Chen, and Y. Xu Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010 Int J Antimicrob Agents 38 2011 376 383
19. G.G. Zhanel, L. Palatnick, and K.A. Nichol Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 Antimicrob Agents Chemother 47 2003 1875 1881
20. Critchley I, Biek D, Sader H, Jones RN, Krause K. Evaluation of pneumococci from the United States (USA) pediatric patients isolated during the 2009 AWARE program (abstract G3-180). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 September 17-20; Chicago, IL.
21. A.I. Hidron, C.E. Low, and E.G. Honig Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia Lancet 9 2009 384 392
22. Infectious Diseases Society of America (IDSA) B. Spellberg, and M. Blaser Combating antimicrobial resistance: policy recommendations to save lives Clin Infect Dis 52 Suppl. 5 2011 S397 S428
23. S.S. Richter, K.P. Heilmann, and C.L. Dohrn Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005 Clin Infect Dis 48 2009 e23 e33
24. T.M. File Jr. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia Clin Microbiol Infect 12 Suppl 3 2006 31 41
25. Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2007. http://www.cdc.gov/ncidod/abcs/reports-findings/ survreports/spneu07.pdf. Accessed April 6, 2012.
26. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis [serial on the Internet]. 2009 August. http://wwwns.cdc.goc/eid/article/15/8/08-1187.htm. Accessed April 6, 2012.
27. S.N. Patel, A. McGeer, R. Melano for the Canadian Bacterial Surveillance Network Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada Antimicrob Agents Chemother 55 2011 3703 3708
28. Centers for Disease Control, Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998-2003 MMWR Morb Mortal Wkly Rep 54 36 2005 893 897
29. C.A. Lexau, R. Lynfield, and R. Danila Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine JAMA 294 2005 2043 2051
30. C.G. Whitney, M.M. Farley, and J. Hadler Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med 348 2003 1737 1746
31. A.F. Messina, K. Katz-Gaynor, and T. Barton Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005 Pediatr Infect Dis J 26 2007 461 467
32. S.I. Pelton, H. Huot, and J.A. Finkelstein Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine Pediatr Infect Dis J 26 2007 468 472
33. R.E. Gertz Jr., Z. Li, and F.C. Pimenta Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era J Infect Dis 201 2010 770 775
34. D.J. Farrell, K.P. Klugman, and M. Pichichero Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States Pediatr Infect Dis J 26 2007 123 128
35. M.R. Moore, R.E. Gertz Jr., and R.L. Woodbury Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005 J Infect Dis 197 2008 1016 1027
36. J.F. Hindler, and J. Stelling Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute Clin Infect Dis 44 2007 867 873
37. A.L. Pakyz The utility of hospital antibiograms as tools for guiding empiric therapy and tracking resistance. Insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 27 2007 1306 1312
38. Jacobs MR, Bajaksouzian S, Good CE, Windau AR, Gonzalez B. Evolution of Streptococcus pneumoniae serotypes following introduction of the 13-valent conjugate pneumococcal vaccine [poster G3-773]. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
39. S.L. Kaplan, W.J. Barson, and P.L. Lin Serotype 19A is the most common serotype causing invasive pneumococcal infections in children Pediatrics 125 2010 429 436
40. L.A. Mandell, and R. Wunderink Methicillin-resistant Staphylococcus aureus and community-acquired pneumonia: an evolving relationship Clin Infect Dis 54 2012 1134 1136
41. R.T. Attridge, and C.R. Frei Increasing incidence of Staphylococcus aureus pneumonia among patients admitted to United States hospitals from community settings Poster presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA 2009
42. M.A. Carillo-Marquez, K.G. Hulten, and W. Hammerman Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital Pediatr Infect Dis 30 2011 545 550
43. G. Erdem, L. Bergert, and K. Len Radiological findings of community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus pediatric pneumonia in Hawaii Pediatr Radiol 40 2010 1768 1773
44. T.M. File Jr., D.E. Low, and P.B. Ekburg Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia Clin Infect Dis 51 2010 1395 1405
45. G.J. Moran, A. Krishnadasan, and R.J. Gorwitz Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia Clin Infect Dis 54 2012 1126 1133
46. M. Rybak, B. Lomaestro, and J.C. Rotschafer Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
47. E. Rubinstein, M.H. Kollef, and D. Nathwani Pneumonia caused by methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 Suppl 5 2008 S378 S385
48. R.M. Klevens, M.A. Morrison, and J. Nadle Invasive methicillin-resistant Staphylococcus aureus infections in the United States JAMA 298 2007 1763 1771
49. G.J. Moran, A. Krishnadasan, and R.J. Gorwitz Methicillin-resistant S. aureus infections among patients in the emergency department N Engl J Med 355 2006 666 674
50. G.J. Moran, R.N. Amii, and F.M. Abrahamian Methicillin-resistant Staphylococcus aureus in community-acquired skin infections Emerg Infect Dis 11 2005 928 930
51. D.J. Pallin, D.J. Egan, and A.J. Pelletier Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus Ann Emerg Med 51 2008 291 298
52. D.A. Talan, A. Krishnadasan, and R.J. Gorwitz Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008 Clin Infect Dis 53 2011 144 149
53. G.S. Tillotson, D.C. Draghi, and D.F. Sahm Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study J Antimicrob Chemother 62 2008 109 115
54. M. David, and R. Daum Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic Clin Microbiol Rev 23 2010 616 687
55. J.S. Francis, M.C. Doherty, and U. Lopatin Severe community-onset pneumonia in healthy adults caused by methicillin-resitant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes Clin Infect Dis 40 2005 100 107
56. J.C. Hageman, T.M. Uyeki, and J.S. Francis Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season Emerg Infect Dis 12 2006 894 899
57. A.J. Kallen, J. Brunkard, and Z. Moore Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season Ann Emerg Med 53 2009 358 365
58. A.J. Kallen, C. Reed, and M. Patton Staphylococcus aureus community-onset pneumonia in patients admitted to children's hospitals during autumn and winter of 2006-07 Epidemiol Infect 138 2010 666 672
59. C. Liu, A. Bayer, and S.E. Cosgrove Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 2011 e18 e55
60. M.J. Rybak, B.M. Lomaestro, and J.C. Rotschafer Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
61. M.S. Niederman, J.S. McCombs, and A.N. Unger The cost of treating community-acquired pneumonia Clin Ther 20 1998 820 837
62. N.C. Dean, J.P. Jones, and D. Aronsky Hospital admission decision for patients with community-acquired pneumonia: variability among physicians in an emergency department Ann Emerg Med 59 2012 35 41
63. M.J. Fine, T.E. Auble, and D.M. Yealy A prediction rule to identify low-risk patients with community-acquired pneumonia N Engl J Med 336 1997 243 250
64. W.S. Lim, M.M. van der Eerden, and R. Laing Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study Thorax 58 2003 377 382
65. J.D. Chalmers, A. Singanayagam, and A.R. Akram Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis Thorax 65 2010 878 883
66. Y.K. Loke, C.S. Kwok, and A. Niruban Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis Thorax 65 2010 884 890
67. P.G. Charles, R. Wolfe, and M. Whitby SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia Clin Infect Dis 47 2008 375 384
68. A.M. Kelly, R. McAlpine, and E. Kyle Venous pH can safely replace arterial pH in the initial evaluation of patients in the emergency department Emerg Med J 18 2001 340 342
69. S.M. Brown, B.E. Jones, and A.R. Jephson Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia Crit Care Med 37 2009 3010 3016
70. A. Liapikou, M. Ferrer, and E. Polverino Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission Clin Infect Dis 48 2009 377 385
71. J.D. Chalmers, J.K. Taylor, and P. Mandal Validation of the Infectious Diseases Society of America/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care Clin Infect Dis 53 2011 503 511
72. G. Moran, and D. Talan Pneumonia, Chapter 75: In: Rosen's emergency medicine: concepts and clinical practice 7th ed. 2010 Mosby/Elsevier Philadelphia, PA
73. D. Nassisi, and M.L. Oishi Evidence-based guidelines for evaluation and antimicrobial therapy for common emergency department infections Emerg Med Pract 14 2012 1 28
74. H. Syrjälä, M. Broas, I. Suramo, A. Ojala, and S. Lähde High-resolution computed tomography for the diagnosis of community-acquired pneumonia Clin Infect Dis 27 1998 358 363
75. F. Cortellaro, S. Colombo, and D. Coen Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department Emerg Med J 29 2012 19 23
76. S. Parlamento, R. Copetti, and S. Di Bartolomeo Evaluation of lung ultrasound for the diagnosis of pneumonia in the ED Am J Emerg Med 27 2009 379 384
77. A.M. Napoli, C.M. Fischer, and J.M. Pines Absolute lymphocyte count in the emergency department predicts a low CD4 count in admitted HIV-positive patients Acad Emerg Med 18 2011 385 389
78. J. Bartlett Diagnostic tests for agents of community-acquired pneumonia Clin Infect Dis 52 Suppl 4 2011 S296 S304
79. M.M. van der Eerden, F. Vlaspolder, and C.S. de Graaff Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study Thorax 60 2005 672 678
80. C. Weatherall, R. Paoloni, and T. Gottlieb Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia Emerg Med J 25 2008 144 148
81. N. Sopena, and M. Sabrià Multicenter study of hospital-acquired pneumonia in non-ICU patients Chest 127 2005 213 219
82. C.C. Ginocchio Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens Clin Infect Dis 52 Suppl. 4 2011 S312 S325
83. S.M. Babin, Y.H. Hsieh, R.E. Rothman, and C.A. Gaydos A meta-analysis of point-of-care laboratory tests in the diagnosis of novel 2009 swine-lineage pandemic influenza A (H1N1) Diagn Microbiol Infect Dis 69 2011 410 418
84. D.J. Faix, S.S. Sherman, and S.H. Waterman Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans N Engl J Med 361 2009 728 729
85. D. Lieberman, A. Shimoni, and Y. Shemer-Avni Respiratory viruses in adults with community-acquired pneumonia Chest 138 2010 811 816
86. L.R. Peterson Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus Clin Infect Dis 52 Suppl. 4 2011 S361 S366
87. US Food and Drug Administration. FDA expands use for FilmArray Respiratory Panel. Press release. May 15, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304177.htm. Accessed June 12, 2012.
88. D.J. Ecker, R. Sampath, and C. Massire Ibis T5000: a universal biosensor approach for microbiology Nat Rev Microbiol 6 2008 553 558
89. D.J. Ecker, R. Sampath, and L.B. Blyn Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance Proc Natl Acad Sci USA 102 2005 8012 8017
90. A. Endimiani, K.M. Hujer, and A.M. Hujer Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis 52 Suppl 4 2011 S373 S383
91. J.J. Oosterheert, A.M. van Loon, and R. Schuurman Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection Clin Infect Dis 41 2005 1438 1444
92. P. Schuetz, M. Christ-Crain, and R. Thomann Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial JAMA 302 2009 1059 1066
93. W. Long, X. Deng, and Y. Zhang Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia Respirology 16 2011 819 824
94. D.T. Huang, L.A. Weissfeld, and J.A. Kellum Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia Ann Emerg Med 52 2008 48 58
95. A.F. Shorr, M.D. Zilberberg, and R. Reichley Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department Clin Infect Dis 54 2012 193 198
96. TYGACIL prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2011.
97. C. Tanaseanu, C. Bergallo, and O. Teglia Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia Diagn Microbiol Infect Dis 61 2008 329 338
98. Y. Cai, R. Wang, and B. Liang Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease Antimicrob Agents Chemother 55 2011 1162 1172
99. TEFLARO [prescribing information]. New York, NY: Forest Laboratories, Inc.; 2012.
100. Joint Commission. Specifications Manual for National Hospital Quality Measures. http://www.jointcommission.org/specifications-manual-for-national- hospital-inpatient-quality-measures/. Accessed November 15, 2011.
101. T.M. File Jr., D.E. Low, and P.B. Eckburg FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia J Antimicrob Chemother 66 Suppl 3 2011 iii19 iii32
102. D.E. Low, T.M. File Jr., and P.B. Eckburg FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia J Antimicrob Chemother 66 Suppl 3 2011 iii33 iii44
103. P.B. Eckburg, H.D. Friedland, and L. Llorens Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia Infect Dis Clin Pract 20 2012 254 260
104. D.R. Rank, H.D. Friedland, and J.B. Laudano Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia J Antimicrob Chemother 66 Suppl 3 2011 iii53 iii59
105. G.R. Corey, M. Wilcox, and G.H. Talbot Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
106. F.C. Tenover, and R.C. Moellering Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus Clin Infect Dis 44 2007 1208 1215
107. G. Steinkraus, R. White, and L. Friedrich Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005 J Antimicrob Chemother 60 2007 788 794
108. P.C. Appelbaum Microbiology of antibiotic resistance in Staphylococcus aureus Clin Infect Dis 45 Suppl 3 2007 S165 S170
109. S.J. van Hal, T.P. Lodise, and D.L. Paterson The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis Clin Infect Dis 54 2012 755 771
110. R.N. Jones, M.G. Stilwell, and P.A. Hogan Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program Antimicrob Agents Chemother 51 2007 1491 1493
111. A.H. Mutnick, D.J. Biedenbach, and D. Turnidge Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000 Diagn Microbiol Infect Dis 43 2002 65 73
112. Zyvox prescribing information. New York, NY: Pfizer, Inc., 2012.
113. D.J. Farrell, R.E. Mendes, and J.E. Ross LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States Antimicrob Agents Chemother 55 2011 3684 3690
114. M. Sánchez García, De la Torre MA, and G. Morales Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit JAMA 303 2010 2260-2264
115. E. Rubinstein, R. Isturiz, and H.C. Standiford Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies Antimicrob Agents Chemother 47 2003 1824 1831
116. D.C. Vinh, and E. Rubinstein Linezolid: a review of safety and tolerability J Infect 59 Suppl 1 2009 S59 S74
117. Food and Drug Administration. FDA Drug Safety Communication: updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications. http://www.fda.gov/Drugs/DrugSafety/ ucm276251.htm. October 2011. Accessed November 15, 2011.